DK0746317T3 - Sublingual eller bukkal farmaceutisk sammensætning - Google Patents

Sublingual eller bukkal farmaceutisk sammensætning

Info

Publication number: DK0746317T3
Authority: DK; Denmark
Prior art keywords: sublingual; pct; pharmaceutical composition; buccal; buccal pharmaceutical
Prior art date: 1994-03-02

Application number

DK95912188T

Other languages

English (en)

Inventor

Leonardus Petrus C Delbressine

Johannes Hubertus Wieringa

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-02

Filing date

1995-03-01

Publication date

1999-03-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0746317(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-03-01 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1999-03-22 Application granted granted Critical

1999-03-22 Publication of DK0746317T3 publication Critical patent/DK0746317T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK95912188T 1994-03-02 1995-03-01 Sublingual eller bukkal farmaceutisk sammensætning DK0746317T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94200521		1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en)	1994-03-02	1995-03-01	Sublingual or buccal pharmaceutical composition

Publications (1)

Publication Number	Publication Date
DK0746317T3 true DK0746317T3 (da)	1999-03-22

Family

ID=8216678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95912188T DK0746317T3 (da)	1994-03-02	1995-03-01	Sublingual eller bukkal farmaceutisk sammensætning

Country Status (23)

Country	Link
US (1)	US5763476A (da)
EP (1)	EP0746317B1 (da)
JP (2)	JP4099224B2 (da)
KR (1)	KR100330942B1 (da)
CN (1)	CN1079670C (da)
AT (1)	ATE167057T1 (da)
AU (1)	AU692530B2 (da)
BR (2)	BR9506924A (da)
CA (1)	CA2182981C (da)
CZ (1)	CZ284633B6 (da)
DE (2)	DE122010000050I2 (da)
DK (1)	DK0746317T3 (da)
ES (1)	ES2118584T3 (da)
FI (1)	FI117923B (da)
FR (1)	FR10C0056I2 (da)
HK (1)	HK1008417A1 (da)
HU (1)	HU225051B1 (da)
LU (1)	LU91751I2 (da)
NO (2)	NO308772B1 (da)
NZ (1)	NZ282394A (da)
PL (1)	PL180465B1 (da)
RU (1)	RU2139051C1 (da)
WO (1)	WO1995023600A1 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999032108A1 (en) *	1997-12-19	1999-07-01	Akzo Nobel N.V.	Org-5222 in the treatment of depression
CA2476250C (en) *	2002-02-13	2010-08-03	Michael K. Weibel	Drug dose-form and method of manufacture
US7276246B2 (en) *	2003-05-09	2007-10-02	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en)	2003-05-09	2007-12-11	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
EP1633400A2 (en) *	2003-05-16	2006-03-15	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
TWI327915B (en) *	2003-06-12	2010-08-01	Organon Nv	Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
CN1905905B (zh) *	2003-09-22	2011-06-08	巴克斯特国际公司	用于药物制剂和医药产品最终灭菌的高压灭菌
JP2007537232A (ja) *	2004-05-11	2007-12-20	ファイザー・プロダクツ・インク	非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
GB0416861D0 (en) *	2004-07-29	2004-09-01	Quadrant Drug Delivery Ltd	Composition
JP2008516925A (ja) *	2004-10-15	2008-05-22	ナームローゼ・フエンノートチヤツプ・オルガノン	双極性障害および随伴症状の治療
US7872147B2 (en)	2005-04-07	2011-01-18	N. V. Organon	Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
RU2405786C2 (ru) *	2005-04-07	2010-12-10	Н.В. Органон	Кристаллическая форма малеата азенапина
RU2397164C2 (ru)	2005-04-07	2010-08-20	Н.В. Органон	ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3f,12b-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]-ОКСЕПИНО[4,5-c]ПИРРОЛА
US7741358B2 (en) *	2005-04-14	2010-06-22	N.V. Organon	Crystal form of asenapine maleate
US7750167B2 (en)	2006-07-05	2010-07-06	N.V. Organon	Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en)	2007-01-05	2011-01-25	Synthon Bv	Process for making asenapine
PE20091156A1 (es) *	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JP2011526881A (ja) *	2008-06-25	2011-10-20	ファイザー・インク	ジアリール化合物およびそれらの使用
WO2010127674A1 (en) *	2009-05-06	2010-11-11	Sunin K/S	Transdermal compositions of asenapine for the treatment of psychiatric disorders
BRPI1011453A2 (pt)	2009-06-24	2016-03-15	Msd Oss Bv	formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
TW201118102A (en)	2009-07-29	2011-06-01	Organon Nv	Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
CA2802990A1 (en)	2010-06-18	2011-12-22	Dr. Reddy's Laboratories Ltd.	Asenapine maleate
US8653280B2 (en)	2010-07-29	2014-02-18	Laboratories Lesvi, S.L.	Process for the preparation of asenapine
WO2012038975A2 (en) *	2010-09-22	2012-03-29	Msn Laboratories Limited	Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
DK3034079T3 (da)	2010-11-15	2018-02-05	Agenebio Inc	Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse
WO2012066565A2 (en)	2010-11-16	2012-05-24	Cadila Healthcare Limited	Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en)	2010-12-13	2012-06-27	Chemo Ibérica, S.A.	Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en)	2011-03-11	2012-09-20	Medichem S.A.	NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en)	2011-05-17	2012-11-21	Sandoz AG	Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
US9533994B2 (en)	2011-05-18	2017-01-03	Laboratorios Lesvi S.L.	Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
US9505771B2 (en) *	2011-05-18	2016-11-29	Laboratories Lesvi S.L.	Stable micronised monoclin form of asenapine maleate and its synthesis
EP2572703A1 (en)	2011-09-21	2013-03-27	Hexal AG	Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en)	2011-09-21	2013-03-28	Sandoz Ag	Crystal form of asenapine maleate
CN102657635B (zh) *	2012-05-04	2013-08-07	上海现代药物制剂工程研究中心有限公司	具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it)	2012-10-24	2014-04-25	Chemo Iberica Sa	Poliformi di maleato di asenapina e processo per la loro preparazione
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US9597291B2 (en)	2012-12-11	2017-03-21	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Orally disintegrating tablet containing asenapine
US10195150B2 (en)	2012-12-20	2019-02-05	Kashiv Pharma, Llc	Orally disintegrating tablet formulation for enhanced bioavailability
CN103893139B (zh) *	2012-12-28	2018-06-08	石药集团中奇制药技术（石家庄）有限公司	一种阿塞那平组合物及其制备方法
CN103120688A (zh) *	2013-01-11	2013-05-29	盛世泰科生物医药技术(苏州)有限公司	一种闪释制剂的药物组合
US9545376B2 (en)	2013-01-23	2017-01-17	Arx, Llc	Production of unit dose constructs
WO2014127786A1 (en)	2013-02-22	2014-08-28	Zentiva, K.S.	Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (da) *	2013-06-28	2015-06-12	Alembic Pharmaceuticals Ltd
CA3123897C (en)	2013-12-20	2024-02-06	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2015125152A2 (en) *	2014-02-18	2015-08-27	Hetero Research Foundation	Pharmaceutical compositions of asenapine
US10077267B2 (en)	2014-04-04	2018-09-18	Intra-Cellular Therapies, Inc.	Organic compounds
TR201509009A1 (en) *	2014-12-11	2017-02-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	THIN FILM STRIP OF ASENAPINE
WO2016198113A1 (en)	2015-06-11	2016-12-15	Alrise Biosystems Gmbh	Process for the preparation of drug loaded microparticles
CN108026107B (zh)	2015-06-19	2021-07-30	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
PL3838274T3 (pl)	2016-01-26	2024-04-02	Intra-Cellular Therapies, Inc.	Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
CA3016353C (en)	2016-03-25	2021-04-27	Intra-Cellular Therapies, Inc.	Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders
US10085971B2 (en)	2016-08-22	2018-10-02	Navinta Iii Inc	Pharmaceutical solution of asenapine for sublingual or buccal use
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt)	2016-12-19	2019-11-26	Agenebio Inc	derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
CA3047451A1 (en)	2016-12-20	2018-06-28	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system containing asenapine
CA3047354A1 (en)	2016-12-20	2018-06-28	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
JP6987868B2 (ja)	2016-12-29	2022-01-05	イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc.	有機化合物
US10961245B2 (en)	2016-12-29	2021-03-30	Intra-Cellular Therapies, Inc.	Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
KR102398194B1 (ko)	2017-03-24	2022-05-18	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 조성물 및 방법
CN110799180A (zh)	2017-06-26	2020-02-14	罗曼治疗系统股份公司	含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
MX2020009668A (es)	2018-03-16	2021-01-08	Intra Cellular Therapies Inc	Métodos novedosos.
WO2019183341A1 (en)	2018-03-23	2019-09-26	Intra-Cellular Therapies, Inc.	Organic compounds
WO2019246300A1 (en)	2018-06-19	2019-12-26	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12329862B2 (en)	2018-06-20	2025-06-17	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system containing asenapine
BR112020026099A2 (pt)	2018-06-20	2021-03-23	Lts Lohmann Therapie-Systeme Ag	sistema terapêutico transdérmico que contém asenapina
WO2020047241A1 (en)	2018-08-29	2020-03-05	Intra-Cellular Therapies, Inc.	Novel compositions and methods
KR20210052472A (ko)	2018-08-31	2021-05-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
BR112021003655A2 (pt)	2018-08-31	2021-05-18	Intra-Cellular Therapies, Inc.	métodos novos
AU2020311894B2 (en)	2019-07-07	2025-06-26	Intra-Cellular Therapies, Inc.	Novel methods
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods
US20240132513A1 (en)	2022-08-19	2024-04-25	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7605526A (nl) *	1976-05-24	1977-11-28	Akzo Nv	Nieuwe tetracyclische derivaten.
IE45770B1 (en) *	1976-10-06	1982-11-17	Wyeth John & Brother Ltd	Pharmaceutical dosage forms
GB1548022A (en) *	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
FR2480283A1 (fr) *	1980-04-10	1981-10-16	Science Union & Cie	Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) *	1982-10-07	1984-04-16	Grelan Pharmaceut Co Ltd	軟質な口腔製剤
GB8613688D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition
CA2027243A1 (en) *	1989-10-17	1991-04-18	Everett H. Ellinwood, Jr.	Intraoral formulated trifluorobenzodiazepines and the use thereof
DE69232374T2 (de) *	1991-04-08	2002-08-29	Koken Co. Ltd., Tokyo	Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
ZA933134B (en) *	1992-05-08	1993-11-30	Akzo Nv	Depot preparation
EP0569096A1 (en) *	1992-05-08	1993-11-10	Akzo Nobel N.V.	Depot preparation

1995
- 1995-03-01 KR KR1019960704774A patent/KR100330942B1/ko not_active Expired - Lifetime
- 1995-03-01 DE DE201012000050 patent/DE122010000050I2/de active Active
- 1995-03-01 EP EP95912188A patent/EP0746317B1/en not_active Expired - Lifetime
- 1995-03-01 DE DE69502939T patent/DE69502939T2/de not_active Expired - Lifetime
- 1995-03-01 HU HU9602383A patent/HU225051B1/hu active Protection Beyond IP Right Term
- 1995-03-01 HK HK98109126A patent/HK1008417A1/en not_active IP Right Cessation
- 1995-03-01 US US08/693,064 patent/US5763476A/en not_active Expired - Lifetime
- 1995-03-01 RU RU96120090/14A patent/RU2139051C1/ru active Protection Beyond IP Right Term
- 1995-03-01 CN CN95191906A patent/CN1079670C/zh not_active Expired - Lifetime
- 1995-03-01 CZ CZ962541A patent/CZ284633B6/cs not_active IP Right Cessation
- 1995-03-01 PL PL95316080A patent/PL180465B1/pl unknown
- 1995-03-01 DK DK95912188T patent/DK0746317T3/da active
- 1995-03-01 CA CA002182981A patent/CA2182981C/en not_active Expired - Lifetime
- 1995-03-01 AT AT95912188T patent/ATE167057T1/de active
- 1995-03-01 JP JP52270395A patent/JP4099224B2/ja not_active Expired - Lifetime
- 1995-03-01 NZ NZ282394A patent/NZ282394A/en not_active IP Right Cessation
- 1995-03-01 ES ES95912188T patent/ES2118584T3/es not_active Expired - Lifetime
- 1995-03-01 WO PCT/EP1995/000765 patent/WO1995023600A1/en not_active Ceased
- 1995-03-01 BR BR9506924A patent/BR9506924A/pt not_active Application Discontinuation
- 1995-03-01 AU AU19478/95A patent/AU692530B2/en not_active Expired
1996
- 1996-08-30 FI FI963398A patent/FI117923B/fi not_active IP Right Cessation
- 1996-08-30 NO NO19963639A patent/NO308772B1/no not_active IP Right Cessation
1997
- 1997-05-13 BR BR1100625-0A patent/BR1100625A/pt active IP Right Grant
2006
- 2006-08-10 JP JP2006217762A patent/JP4616810B2/ja not_active Expired - Lifetime
2010
- 2010-11-04 LU LU91751C patent/LU91751I2/fr unknown
- 2010-12-13 NO NO2010024C patent/NO2010024I2/no unknown
- 2010-12-23 FR FR10C0056C patent/FR10C0056I2/fr active Active

Also Published As

Publication number	Publication date
JPH09509674A (ja)	1997-09-30
FI963398A0 (fi)	1996-08-30
EP0746317A1 (en)	1996-12-11
US5763476A (en)	1998-06-09
ES2118584T3 (es)	1998-09-16
WO1995023600A1 (en)	1995-09-08
AU1947895A (en)	1995-09-18
CZ254196A3 (en)	1997-10-15
RU2139051C1 (ru)	1999-10-10
FI963398L (fi)	1996-08-30
DE69502939D1 (de)	1998-07-16
HUT76319A (en)	1997-08-28
HU9602383D0 (en)	1996-10-28
PL180465B1 (pl)	2001-02-28
NO2010024I1 (no)	2011-01-03
CN1143320A (zh)	1997-02-19
NO963639D0 (no)	1996-08-30
NO2010024I2 (no)	2012-04-10
DE122010000050I2 (de)	2011-07-21
FI117923B (fi)	2007-04-30
MX9603713A (es)	1997-12-31
NO308772B1 (no)	2000-10-30
CZ284633B6 (cs)	1999-01-13
CA2182981A1 (en)	1995-09-08
FR10C0056I1 (da)	2011-01-28
NZ282394A (en)	1997-12-19
ATE167057T1 (de)	1998-06-15
BR9506924A (pt)	1997-09-30
LU91751I2 (fr)	2011-01-04
EP0746317B1 (en)	1998-06-10
JP2006342178A (ja)	2006-12-21
JP4616810B2 (ja)	2011-01-19
NO963639L (no)	1996-10-30
CN1079670C (zh)	2002-02-27
CA2182981C (en)	2006-10-17
DE122010000050I1 (de)	2011-05-05
HU225051B1 (en)	2006-05-29
AU692530B2 (en)	1998-06-11
HK1008417A1 (en)	1999-05-07
BR1100625A (pt)	1999-12-28
FR10C0056I2 (da)	2011-11-25
DE69502939T2 (de)	1998-10-22
KR100330942B1 (ko)	2002-11-16
JP4099224B2 (ja)	2008-06-11
PL316080A1 (en)	1996-12-23

Publication	Publication Date	Title
DK0746317T3 (da)	1999-03-22	Sublingual eller bukkal farmaceutisk sammensætning
CA2293823A1 (en)	1998-12-17	4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
UA70298A (uk)	2004-10-15	Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
AUPR213700A0 (en)	2001-01-25	Antiviral agents
KR960701051A (ko)	1996-02-24	이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
AU2672995A (en)	1995-12-21	{a}-annelated pyrrole derivatives and pharmaceutical uses thereof
IL113566A0 (en)	1995-08-31	Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
EE03262B1 (et)	2000-04-17	Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
AU3563695A (en)	1996-05-31	Novel piperidine derivatives with paf antagonist activity
CA2314154A1 (en)	1999-07-01	Azepine or larger medium ring derivatives and their use as pharmaceuticals
SI0863752T1 (en)	2003-06-30	Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
GR3034142T3 (en)	2000-11-30	Composition for the treatment or prevention of herpes
IL115004A (en)	2000-10-31	Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation